Singulair®
Montelukast is a leukotriene receptor antagonist for prophylaxis and chronic treatment of asthma and relief of allergic rhinitis.
| Dosage Form | Oral Tablet / Chewable Tablet / Granules |
| Strength | 4 mg, 5 mg, 10 mg |
| Storage | Store at 25°C. Protect from moisture and light. |
| Category | Respiratory |
| Availability | Available for Transfer |
Prophylaxis and chronic treatment of asthma (≥12 months); seasonal and perennial allergic rhinitis; exercise-induced bronchoconstriction prevention.
Selectively blocks leukotriene D4 (LTD4) at the CysLT1 receptor, reducing bronchoconstriction, mucus secretion, vascular permeability, and eosinophilic inflammation.
Each Burrard Pharmaceuticals technology transfer package for Montelukast includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.